Stockscreener 앱 받기
0.86
1.95%
-0.0034
전일 마감가:
$0.8566
열려 있는:
$0.8566
하루 거래량:
557
Relative Volume:
0.00
시가총액:
$57.42M
수익:
$9.53M
순이익/손실:
$-44.61M
주가수익비율:
-0.9451
EPS:
-0.91
순현금흐름:
$-38.32M
1주 성능:
+12.41%
1개월 성능:
-16.83%
6개월 성능:
-45.09%
1년 성능:
-39.68%
1일 변동 폭
$0.8566
$0.8566
1주일 범위
$0.7411
$0.8599
52주 변동 폭
$0.45
$2.26
Cue Biopharma Inc Stock (CUE) Company Profile
명칭
Cue Biopharma Inc
전화
617-949-2680
주소
40 GUEST STREET, BOSTON, MA
CUE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CUE
Cue Biopharma Inc
|
0.8566 | 57.42M | 9.53M | -44.61M | -38.32M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.12 | 125.74B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.58 | 61.57B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.12 | 36.40B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.15 | 30.36B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
248.12 | 24.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-03-13 | 개시 | Jefferies | Buy |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2022-11-21 | 개시 | Piper Sandler | Overweight |
| 2022-01-13 | 개시 | H.C. Wainwright | Buy |
| 2022-01-03 | 개시 | Craig Hallum | Buy |
| 2020-11-24 | 개시 | Berenberg | Buy |
| 2020-04-09 | 개시 | Stifel | Buy |
| 2020-01-28 | 개시 | BTIG Research | Buy |
| 2020-01-22 | 개시 | JMP Securities | Mkt Outperform |
모두보기
Cue Biopharma Inc 주식(CUE)의 최신 뉴스
Cue Biopharma stock holds $2 target, Market Outperform rating - Investing.com Australia
Cue Biopharma stock holds $2 target, Market Outperform rating By Investing.com - Investing.com South Africa
Petri Dish: Roche unloads drug to Cambridge biotech, Cue and Boehringer link up - The Business Journals
Cue Biopharma stock falls after pricing capital raise of $20M via securities offering - MSN
Cue Biopharma Inc Announces $20 Million Public Offering Amidst C - GuruFocus
Boehringer and Cue Biopharma to develop autoimmune therapies - Pharmaceutical Technology
Boehringer Ingelheim, Cue Biopharma partner to develop next generation treatment for autoimmune,... - Medical Dialogues
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Cue Biopharma (CUE) Partners with Boehringer Ingelheim to Advance B Cell Therapy | CUE Stock News - GuruFocus
Boehringer’s bispecific pact with Cue Biopharma; HepaRegeniX raises €21.5M - Endpoints News
Cue Biopharma Rises On Partnership With Boehringer To Develop CUE-501 For Autoimmune Diseases - Nasdaq
Boehringer Ingelheim, Cue Biopharma Partner to Commercialize Therapy for Immune Diseases - Contract Pharma
Boehringer Ingelheim and Cue Biopharma agree to advance CUE-501 for autoimmune diseases - BioWorld MedTech
Cue stock in focus after pact with Boehringer (CUE:NASDAQ) - Seeking Alpha
Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases - Lelezard
Boehringer and Cue Biopharma partner to develop next-generation treatments - The Pharma Letter
Cue Biopharma stock holds $2 target, JMP reiterates rating By Investing.com - Investing.com India
Cue Biopharma stock holds $2 target, JMP reiterates rating - Investing.com Australia
Cue Biopharma (CUE) Launches Public Offering of Common Stock and Warrants | CUE Stock News - GuruFocus
Cue Biopharma to Host Business Update Call and Webcast | CUE Sto - GuruFocus
Cue Biopharma Prices $20 Million Public Offering of Stock, Warrants - marketscreener.com
Boehringer Ingelheim and Cue Biopharma partner to develop next-g - GuruFocus
Cue Biopharma Announces Proposed Public Offering | CUE Stock New - GuruFocus
Cue Biopharma (CUE) Stock Dips Amid $20M Public Offering Announcement - GuruFocus
Cue Biopharma Prices About $20 Mln Public Offering - Nasdaq
Cue Biopharma Announces Pricing of Approximately $20 Million Pub - GuruFocus
Cue Biopharma Prices Common Stock And Warrants At $0.79 Per Share; Pre-Funded Warrants At $0.789 - MarketScreener
$20M Capital Raise: Inside Cue Biopharma's Latest Strategic Financing Move - Stock Titan
Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering - The Manila Times
Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering - Benzinga
Boehringer, Cue Biopharma ink autoimmune therapy deal By Investing.com - Investing.com South Africa
Cue Biopharma inks deal with Boehringer Ingelheim By Investing.com - Investing.com South Africa
Cue Biopharma launches public stock offering By Investing.com - Investing.com Canada
Cue Biopharma launches public stock offering - Investing.com Australia
Boehringer Ingelheim, Cue Biopharma Partner To Develop Autoimmune And Inflammatory Disease Treatments - MarketScreener
Cue Biopharma inks deal with Boehringer Ingelheim - Investing.com
Boehringer, Cue Biopharma ink autoimmune therapy deal - Investing.com
Form 424B5 Cue Biopharma, Inc. - StreetInsider
Cue Biopharma Announces Proposed Public Offering - The Manila Times
Cue Biopharma to Host Business Update Call and Webcast - Enidnews.com
Boehringer Ingelheim and Cue Biopharma partner to develop - GlobeNewswire
Cue Biopharma to Reveal Latest Progress in Cancer and Autoimmune Therapeutics - Stock Titan
‘Buy These Two Chip Stocks Ahead of a Recession,’ Says Citi - The Globe and Mail
S&P 500 jumps 1.8% as Wall Street closes a chaotic and historic week - The Globe and Mail
Can Spotify’s (SPOT) Ad Business Hit the Right Notes in 2025? - The Globe and Mail
Seeking High Dividend Yield? Earn 9.6% from This Energy Stock Now. - The Globe and Mail
EXL Schedules First Quarter 2025 Financial Results Conference Call - The Globe and Mail
Will Tariffs Destroy This Clothing Giant? - The Globe and Mail
Cue Biopharma Inc (CUE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.63%
자본화:
|
볼륨(24시간):